These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34285278)

  • 21. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.
    Fletcher O; Johnson N; Dos Santos Silva I; Kilpivaara O; Aittomäki K; Blomqvist C; Nevanlinna H; Wasielewski M; Meijers-Heijerboer H; Broeks A; Schmidt MK; Van't Veer LJ; Bremer M; Dörk T; Chekmariova EV; Sokolenko AP; Imyanitov EN; Hamann U; Rashid MU; Brauch H; Justenhoven C; Ashworth A; Peto J
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):230-4. PubMed ID: 19124502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.
    CHEK2 Breast Cancer Case-Control Consortium
    Am J Hum Genet; 2004 Jun; 74(6):1175-82. PubMed ID: 15122511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis.
    Liang M; Zhang Y; Sun C; Rizeq FK; Min M; Shi T; Sun Y
    Mol Diagn Ther; 2018 Aug; 22(4):397-407. PubMed ID: 29909568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications.
    Muranen TA; Greco D; Fagerholm R; Kilpivaara O; Kämpjärvi K; Aittomäki K; Blomqvist C; Heikkilä P; Borg A; Nevanlinna H
    Breast Cancer Res; 2011 Sep; 13(5):R90. PubMed ID: 21542898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
    Smid M; Schmidt MK; Prager-van der Smissen WJC; Ruigrok-Ritstier K; Schreurs MAC; Cornelissen S; Garcia AM; Broeks A; Timmermans AM; Trapman-Jansen AMAC; Collée JM; Adank MA; Hooning MJ; Martens JWM; Hollestelle A
    Breast Cancer Res; 2023 May; 25(1):53. PubMed ID: 37161532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of CHEK2*1100delC in New York breast cancer cases and controls.
    Offit K; Pierce H; Kirchhoff T; Kolachana P; Rapaport B; Gregersen P; Johnson S; Yossepowitch O; Huang H; Satagopan J; Robson M; Scheuer L; Nafa K; Ellis N
    BMC Med Genet; 2003 Jan; 4():1. PubMed ID: 12529183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
    Muranen TA; Blomqvist C; Dörk T; Jakubowska A; Heikkilä P; Fagerholm R; Greco D; Aittomäki K; Bojesen SE; Shah M; Dunning AM; Rhenius V; Hall P; Czene K; Brand JS; Darabi H; Chang-Claude J; Rudolph A; Nordestgaard BG; Couch FJ; Hart SN; Figueroa J; García-Closas M; Fasching PA; Beckmann MW; Li J; Liu J; Andrulis IL; Winqvist R; Pylkäs K; Mannermaa A; Kataja V; Lindblom A; Margolin S; Lubinski J; Dubrowinskaja N; Bolla MK; Dennis J; Michailidou K; Wang Q; Easton DF; Pharoah PD; Schmidt MK; Nevanlinna H
    Breast Cancer Res; 2016 Oct; 18(1):98. PubMed ID: 27716369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: not present in the Chinese familial breast cancer population.
    Chen W; Yurong S; Liansheng N
    Adv Ther; 2008 May; 25(5):496-501. PubMed ID: 18484200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study.
    Johnson N; Fletcher O; Naceur-Lombardelli C; dos Santos Silva I; Ashworth A; Peto J
    Lancet; 2005 Oct 29-Nov 4; 366(9496):1554-7. PubMed ID: 16257342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a novel BRCA2 and CHEK2 A-C-G-C haplotype in Turkish patients affected with breast cancer.
    Haytural H; Yalcinkaya N; Akan G; Arikan S; Ozkok E; Cakmakoglu B; Yaylim I; Aydin M; Atalar F
    Asian Pac J Cancer Prev; 2013; 14(5):3229-35. PubMed ID: 23803109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia.
    Thirthagiri E; Cheong LS; Yip CH; Teo SH
    Fam Cancer; 2009; 8(4):355-8. PubMed ID: 19399639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation.
    Baeyens A; Claes K; Willems P; De Ruyck K; Thierens H; Vral A
    Cancer Genet Cytogenet; 2005 Dec; 163(2):106-12. PubMed ID: 16337852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CHEK2 Germ Line Mutations are Lacking among Familial and Sporadic Breast Cancer Patients in Rwanda.
    Habyarimana T; Attaleb M; Mugenzi P; Mazarati JB; Bakri Y; El Mzibri M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):375-379. PubMed ID: 29479983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
    Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
    Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
    Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
    J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
    Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
    J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.
    de Bock GH; Mourits MJ; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    Int J Gynecol Cancer; 2006; 16 Suppl 2():552-5. PubMed ID: 17010071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.
    Adank MA; Jonker MA; Kluijt I; van Mil SE; Oldenburg RA; Mooi WJ; Hogervorst FB; van den Ouweland AM; Gille JJ; Schmidt MK; van der Vaart AW; Meijers-Heijboer H; Waisfisz Q
    J Med Genet; 2011 Dec; 48(12):860-3. PubMed ID: 22058428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CHEK2 1100DELC germline mutation: a frequency study in hereditary breast and colon cancer Brazilian families.
    Abud J; Koehler-Santos P; Ashton-Prolla P; Prolla JC;
    Arq Gastroenterol; 2012 Dec; 49(4):273-8. PubMed ID: 23329222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.